Dec 19 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH + LOMB ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION 0.024%) NOW PUBLICLY COVERED UNDER THE ONTARIO PUBLIC DRUG BENEFIT (ODB) PROGRAM
* BAUSCH + LOMB CANADA - VYZULTA WILL BE ADDED TO ONTARIO DRUG BENEFIT FORMULARY ON DEC. 20, 2019